Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by proneon Aug 31, 2023 9:34am
137 Views
Post# 35613508

Key points

Key points
  • MediPharm Labs wholly owned subsidiary Harvest Medicine has published a study in the peer-reviewed American Journal of Endocannabinoid Medicine.
  • This is the largest peer reviewed published study of its kind on Fibromyalgia and cannabis, with over 800 patient assessments.
  • Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.
  • The study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety.
<< Previous
Bullboard Posts
Next >>